There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation. Lisata Therapeutics Inc ...

Lisata Therapeutics Inc (NASDAQ:LSTA) has advanced its development portfolio, particularly with its novel product candidate, certepatide, for treating advanced solid tumors. Preliminary results from ...

Lisata is also partnering with Valo Therapeutics (ValoTx) to investigate the benefits ... This was primarily due to a reduction in expenses associated with the Phase 2b ASCEND trial which completed ...

As mentioned on prior calls, the ASCEND trial is an investigator initiated trial that Lisata inherited upon our acquisition of Cend Therapeutics. The original trial was designed with more of an ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) had its price target reduced by research analysts at Ascendiant Capital Markets from $33.00 to $24.00 in a research note issued to investors on ...